Obscure gastrointestinal bleeding (OGIB), defined in 2010, involves bleeding from the GI tract that remains unexplained after standard diagnostic procedures. OGIB, which accounts for about 5% of all GI bleeds, poses diagnostic and management challenges, particularly due to the anatomical features of the small intestine. Advances in capsule endoscopy (CE) and balloon‐assisted endoscopy have improved the diagnostic and therapeutic landscape for small intestinal lesions.ObjectiveTo determine the recurrence rate and identify risk factors for recurrence following diagnostic and therapeutic interventions using CE and balloon‐assisted endoscopy in patients with OGIB.MethodsA retrospective cohort study at Gifu University Hospital analyzed CE procedures for patients with OGIB from 2008 to 2022. Patients underwent CE with subsequent treatments based on the findings. Statistical analyses, including Kaplan‐Meier and Cox proportional hazards models, were used to estimate cumulative recurrence rates and identify recurrence risk factors.ResultsOut of 417 patients, 65.2% had positive CE findings, leading to therapeutic interventions in 16.3% of cases. The cumulative recurrence rates at 12, 24, and 36 months were 4.3%, 9.0%, and 13.9%, respectively. Liver cirrhosis (hazard rate: 4.15, 95% confidence interval 1.88–9.18, p < 0.01) was identified as a significant risk factor for recurrence.ConclusionsA significant recurrence rate in OGIB patients, with liver cirrhosis being a major risk factor. Despite diagnostic and therapeutic advances, a comprehensive approach including careful follow‐up and consideration of risk factors is essential for management.